TY - JOUR
T1 - Idiopathic esophageal ulceration in patients infected with human immunodeficiency virus.
AU - Vega, K. J.
AU - Bollu, J.
AU - Dajani, E. Z.
AU - Trotman, B. W.
PY - 1996
Y1 - 1996
N2 - Esophageal disease is a common and important cause of morbidity and mortality in patients with human immunodeficiency virus (HIV) infection. The etiology of HIV-related esophageal ulceration varies. After all known etiologies are excluded, a subgroup of patients remains with esophageal ulceration known as idiopathic esophageal ulceration (IEU). Establishing a diagnosis of IEU is critical and precludes unnecessary treatment with antiviral, antifungal, or antibiotic agents. A review of the current literature indicates that there are no prospective, placebo-controlled, randomized, double-blind trials on the specific treatment of IEU. Several preliminary reports suggest that corticosteroids and thalidomide may be effective. The incidence and natural history of IEU are incompletely known. It is important to establish that any potential therapeutic agents employed to treat IEU do not increase viral replication or provide viral protection. There is a need for well-designed, placebo-controlled, prospective studies to assess the risks and benefits of corticosteroids, thalidomide, and other agents in the treatment of idiopathic esophageal ulceration.
AB - Esophageal disease is a common and important cause of morbidity and mortality in patients with human immunodeficiency virus (HIV) infection. The etiology of HIV-related esophageal ulceration varies. After all known etiologies are excluded, a subgroup of patients remains with esophageal ulceration known as idiopathic esophageal ulceration (IEU). Establishing a diagnosis of IEU is critical and precludes unnecessary treatment with antiviral, antifungal, or antibiotic agents. A review of the current literature indicates that there are no prospective, placebo-controlled, randomized, double-blind trials on the specific treatment of IEU. Several preliminary reports suggest that corticosteroids and thalidomide may be effective. The incidence and natural history of IEU are incompletely known. It is important to establish that any potential therapeutic agents employed to treat IEU do not increase viral replication or provide viral protection. There is a need for well-designed, placebo-controlled, prospective studies to assess the risks and benefits of corticosteroids, thalidomide, and other agents in the treatment of idiopathic esophageal ulceration.
UR - http://www.scopus.com/inward/record.url?scp=0029680518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029680518&partnerID=8YFLogxK
M3 - Review article
C2 - 8936935
AN - SCOPUS:0029680518
SN - 1048-9886
VL - 7
SP - 93
EP - 98
JO - Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians
JF - Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians
IS - 4
ER -